Seven findings from the mRNA vaccines research record
Computed from 16 clinical trials, 30 papers and 7 NIH grants as the records stand on 2 Nov 2026. Hover a figure for its values, click a trial or paper to open the record, or ask a follow-up question.
01
Six of the 16 mRNA vaccines trials in the record start in 2024, more than in the six earlier years combined.
02
12 of 16 mRNA vaccines trials are individualized neoantigen mRNA.
03
Eight of 16 trials are recruiting patients now; one has posted results.
04
One trial accounts for 67% of the 130 places where patients can enroll; 12 of 16 run at one site or have none listed yet.
05
51 of the 149 research places in the record are in the United States; Peking Union Medical College Hospital hosts the most trials, three.
- Memorial Sloan Kettering Cancer Center3
- Washington University in St. Louis2
- Barnes-Jewish Hospital2
- Johns Hopkins University2
- University of California, Los Angeles2
- University of California, San Francisco2
- Think Therapeutics, Inc.1
- Ampedrna Biosciences Llc1
- Fred Hutchinson Cancer Research Center1
Outside this map: 21 in China, 13 in Germany, 10 in Spain, 9 in South Korea, 8 in United Kingdom, 5 in BE, 5 in France, 4 in Australia, 3 in Netherlands, 3 in TW, 3 in SG, 2 in HK, 2 in NZ, 2 in SE, 1 in PL, 1 in PK, 1 in GR.
06
mRNA vaccines saw papers or trials in nine years and NIH money in four; they coincide in four.
07